|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Eplerenone#Adult Indications and Dosage]] |
| {{Eplerenone}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Dosage and Administration==
| |
| | |
| ===2.1 Congestive Heart Failure Post-Myocardial Infarction===
| |
| | |
| Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. INSPRA may be administered with or without food.
| |
| | |
| Once treatment with INSPRA has begun, adjust the dose based on the serum potassium level as shown in Table 1.
| |
| | |
| {|
| |
| |[[File:Eplerenone01.jpg|thumb|800px]]
| |
| |}
| |
| ===2.2 Hypertension===
| |
| The recommended starting dose of INSPRA is 50 mg administered once daily. The full therapeutic effect of INSPRA is apparent within 4 weeks. For patients with an inadequate blood pressure response to 50 mg once daily the dosage of INSPRA should be increased to 50 mg twice daily. Higher dosages of INSPRA are not recommended because they have no greater effect on blood pressure than 100 mg and are associated with an increased risk of [[hyperkalemia]]. [See CLINICAL STUDIES (14.2).]
| |
| | |
| ===2.3 Recommended Monitoring===
| |
| | |
| Serum potassium should be measured before initiating INSPRA therapy, within the first week, and at one month after the start of treatment or dose adjustment. Serum potassium should be assessed periodically thereafter. Patient characteristics and serum potassium levels may indicate that additional monitoring is appropriate. [SeeWARNINGS AND PRECAUTIONS (5.1), ADVERSE REACTIONS (6.2).] In the EPHESUS study [See CLINICAL STUDIES (14.1)], the majority of [[hyperkalemia]] was observed within the first three months after randomization.
| |
| | |
| In all patients taking INSPRA who start taking a moderate CYP3A4 inhibitor, check serum potassium and serum creatinine in 3–7 days.
| |
| | |
| ===2.4 Dose Modifications for Specific Populations===
| |
| | |
| For hypertensive patients receiving moderate CYP3A4 inhibitors (e.g., [[erythromycin]], [[saquinavir]], [[verapamil]], and [[fluconazole]]), the starting dose of INSPRA should be reduced to 25 mg once daily. [See DRUG INTERACTIONS (7.1).]
| |
| | |
| No adjustment of the starting dose is recommended for the elderly or for patients with mild-to-moderate [[hepatic impairment]]. [See CLINICAL PHARMACOLOGY (12.3).]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INSPRA (EPLERENONE) TABLET, FILM COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a55a39ff-1bd5-428b-a64f-c44262e2f3ed | publisher = | date = | accessdate = 28 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Aldosterone antagonists]]
| |
| [[Category:Pfizer]]
| |
| [[Category:Lactones]]
| |
| [[Category:Epoxides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |